Premium
Unicycive Therapeutics Inc (UNCY)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosph... Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -3.6086 | -46.5025773196 | 7.76 | 8.56 | 3.93 | 2809139 | 7.5003345 | CS |
| 4 | -3.6786 | -46.9808429119 | 7.83 | 8.56 | 3.93 | 1542191 | 7.38488949 | CS |
| 12 | -2.4686 | -37.2900302115 | 6.62 | 8.74 | 3.93 | 916607 | 7.43434928 | CS |
| 26 | -1.7586 | -29.7563451777 | 5.91 | 8.74 | 3.93 | 722636 | 7.07092327 | CS |
| 52 | -1.2986 | -23.8275229358 | 5.45 | 8.74 | 3.71 | 610436 | 6.118667 | CS |
| 156 | 2.8514 | 219.338461538 | 1.3 | 8.74 | 0.202 | 966474 | 1.84241665 | CS |
| 260 | -4.3986 | -51.4456140351 | 8.55 | 8.74 | 0.202 | 964183 | 1.91530336 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
